

Arkansas Blue Cross and Blue Shield Federal Employee Program Medical Pharmacy Prior Approval Program

Magellan Rx Management is an independent company that operates separately from Arkansas Blue Cross and Blue Shield and administers medical specialty drug program services for the benefit of Arkansas Blue Cross Federal Employee Program members. Arkansas Blue Cross and Blue Shield is an independent licensee of the Blue Cross Blue Shield Association.

MagellanRx
MANAGEMENTSM


Agenda

- 1 Program Overview
- 2 Review Process
- 3 Magellan Rx Provider Portal
- 4 Resources

Program Overview




Program Overview




- ✓ Effective **March 1, 2022**, Arkansas Blue Cross and Blue Shield will be implementing a change in how **certain specialty drugs** are managed for its Federal Employee Program (FEP) members.
- ✓ This new program will be administered by **Magellan Rx Management** (Magellan Rx). Magellan Rx will be responsible for reviewing and approving these drugs.
- ✓ Beginning **February 21, 2022**, providers may begin contacting Magellan Rx to obtain **prior approval** for members who will receive treatment/drugs within the scope of this program **on or after March 1, 2022**.

Places of Service



Prior approval is required by Magellan Rx when the drugs are administered by practitioners in the following places of service (POS)




Impacted Members

The program will apply to members enrolled in the following plans:

- Federal Employee Program **Standard**
- Federal Employee Program **Basic**
- Federal Employee Program **Blue Focus**



Transition of Care Process




Date of Service

- **Prior approvals** issued for dates of service **before March 1, 2022**, for the medications identified as part of this program will be **effective until the prior approval end date**.

End Date

- **Claims** for dates of services **after** the prior approval end date will be **denied** if the provider has not obtained a successive prior approval from Magellan Rx.



Validity Date

- To **continue treatment** after the original prior approval validity date, you must obtain a **successive prior approval** from Magellan Rx prior to the expiration date.

Drugs Requiring Prior Approval through Magellan Rx




HCPCS	Brand Name	HCPCS	Brand Name	HCPCS	Brand Name	HCPCS	Brand Name	HCPCS	Brand Name	HCPCS	Brand Name
J3262	Actemra	J3590	Cutaquig	J7320	GenVisc	J0888	Mircera (non ESRD)	J1745	Remicade	J9317	Trodelvy
J0791	Adakveo	J1555	Cuvitru	J0257	Glassia	J7327	Monovisc	J3285	Remodulin	Q5115	Truxima
J9042	Adcetris	J9308	Cyramza	J1447	Granix	Q5107	Mvasi	Q5104	Renflexis	J2323	Tysabri
J1454	Akynzeo	J9145	Darzalex	J0800	H. P. Acthar	J0587	Myobloc	Q5106	Retacrit	Q5111	Udenyca
J1454	Akynzeo IV	J9144	Darzalex Faspro	J0599	Haegarda	J2506	Neulasta	J3490	Revatio	J1303	Ultomiris
J2469	Aloxi	J7318	Durolane	J9179	Halaven	J1442	Neupogen	J9312	Rituxan	J1823	Uplizna
J0256	Aralast	J0586	Dysport	J9355	Herceptin	Q5110	Nivestym	J9311	Rituxan Hycela	J9303	Vectibix
J0881	Aranesp (non-ESRD)	J3060	Elelyso	J9356	Herceptin Hylecta	J2796	Nplate	J0596	Ruconest	J9041	Velcade
J9302	Arzerra	J9176	Empliciti	Q5113	Herzuma	J2182	Nucala	Q5119	Ruxience	J1325	Veletri
J1554	Asceniv	J9358	Enhertu	J1559	Hizentra	Q5122	Nyvepria	J2353	Sandostatin LAR Depot	J7321	Visco-3
J9035	Avastin (oncology only)	J3380	Entyvio	J7321	Hyalgan	J2350	Ocrevus	J2502	Signifor_LAR	J3385	Vpriv
Q5121	Avsola	J1325	Epoprostenol	J7322	Hymovis	J1568	Octagam	J1602	Simponi Aria	J3032	Vyepti
J9023	Bavencio	J9055	Erbix	J1575	HyQvia	Q5114	Ogivri	J7331	Sodium Hyaluronate	J1429	Vyondys 53
J9032	Beleodaq	J7323	Euflexxa	J3245	Ilumya	J9205	Onivyde	J1300	Soliris	J1558	Xembify
J9036	Belrapzo	J3111	Evenity	J9173	Imfinzi	J0222	Onpattro	J1930	Somatuline depot	J0588	Xeomin
J9034	Bendeka	J1428	Exondys	Q5103	Inflectra	Q5112	Ontruzant	J2326	Spinraza	J0897	Xgeva/Prolia
J0490	Benlysta	J0178	Eylea	J9043	Jevtana	J9299	Opdivo	J3358	Stelara IV	J2357	Xolair
J0179	Beovu	J0517	Fasenra	J9354	Kadcyla	J0129	Orencia	J3490	Strensiq	J9228	Yervoy
J0597	Beriner	J9155	Firmagon	J1290	Kalbitor	J7324	Orthovisc	J7321	Supartz/Supartz FX	J9352	Yondelis
J9229	Besponsa	J1572	Flebogamma	Q5117	Kanjinti	J9177	Padcev	J1627	Sustol	J9400	Zaltrap
J1556	Bivigam	J1325	Flolan	J9271	Keytruda	J1599	Panzyga	90378	Synagis	Q5101	Zarxio
J9039	Blinicyto	Q5108	Fulphila	J2507	Krystexxa	J9306	Perjeta	J7331	Synjoint	J0256	Zemaira
J9044	Bortezomib	J1569	Gammagard Liquid	J9047	Kyprolis	J9309	Polivy	J7325	Synvisc	J9223	Zepzelca
J0585	Botox	J1566	Gammagard S/D (powder)	J0202	Lemtrada	J9295	Portrazza	J7325	Synvisc One	Q5120	Ziextenzo
J1566	Carimune NF	J1561	Gammaked	J2820	Leukine	J9204	Poteligeo	J9022	Tecentriq	Q5118	Zirabev
J1786	Cerezyme	J1557	Gammaplex	J9119	Libtayo	J1459	Privigen	J3241	Tepezza	J9202	Zoladex
J0717	Cimzia	J1561	Gamunex-C	J2778	Lucentis	J0885	Procrit/Epogen (non ESRD)	S0189	Testopel	J3399	Zolgensma
J2786	Cinqair	J9301	Gazyva	J3398	Luxturna	J0256	Prolastin/Prolastin C	Q5116	Trazimera		
J0598	Cinryze	J7326	Gel-One	J2503	Macugen	Q2043	Provenge	J9033	Treanda		
J0584	Crysvita	J7328	Gelsyn			J1301	Radicava	J7332	Triluron		

Other drugs may require prior approval through Arkansas Blue Cross and Blue Shield, and the above list is subject to change. To view the medical policies, please visit <https://www.arkansasbluecross.com/providers/resource-center/specialty-pharmacy>.

Review Process



Provider Responsibilities



Ordering
Provider


Responsible for obtaining the prior approval before services are provided.



Rendering
Provider

Responsible for ensuring that the prior approval was obtained prior to services being rendered.

Information Needed



Provider

- Ordering Provider Name
- Tax ID
- Address
- Office Telephone Number

(Same information is needed for Rendering Provider if different from Ordering Provider)



Member

- Member Name
- Date of Birth
- ID Number
- Height
- Weight
- Diagnosis Code



Medication

- Place of Service Code
- Requested Drug Name or HCPCS Code
- Dosage
- Frequency
- Anticipated Start Date of Treatment





Clinical

- Clinical notes
- Pathology Reports
- Relevant Test Results

If additional information is requested by Magellan Rx, the practitioner should be prepared to upload documents on the provider portal or to fax documents to Magellan Rx HIPAA-compliant fax.

Determination Process Flow



Magellan Rx Website



Obtaining an Online Account



Providers directly contracted with Arkansas Blue Cross and Blue Shield may create an online account for Prior Approvals:


1. Visit our self-service provider portal at www.mrxgateway.com
2. Click on **New Provider Access Request** under the Sign In box
3. Complete the form to request access

The screenshot displays the MagellanRx Management website interface. At the top left is the MagellanRx logo, and at the top right is a 'Contact Us' link. Below the header is a blue banner with the text 'Medical Pharmacy Prior Authorization' and a decorative graphic of colorful circles and icons. A left-hand navigation menu contains sections for 'Provider Resources', 'Health Plan Resources', 'Clinical Guidelines', and 'Forms'. The main content area features a 'Welcome' message above a 'Sign In' form. The form includes fields for 'Username' (containing 'ljcorbett@MagellanHealth.com') and 'Password' (masked with dots), a 'Remember me' checkbox, and a 'Sign In' button. Below the form is a link for 'New Provider Access Request' and a footer with 'Terms of Use | Privacy Policy | Disclaimer'.

Resources



Prior Approval Resources



For routine
Requests,
visit

www.mrxgateway.com



For urgent or
expedited requests
call Magellan Rx at
800-443-5709

Staff available **24 hours a day** for urgent requests by phone (including after hours, weekends and holidays).

If you have claim, benefits and/or eligibility questions, please call Arkansas Blue Cross and Blue Shield (Monday – Friday, 8 a.m.-5 p.m. CST at **800-482-6655**)

A collection of colorful triangles in shades of blue, orange, yellow, and green, scattered across the slide. Some are larger and more prominent, while others are smaller and more subtle. They are arranged in a way that suggests movement or a trail.

THANK YOU!

Lisa J. Corbett, MBA
Director of Provider Relations
MRxPR@magellanhealth.com